


## PIT

<b>Cat. No.:</b>	HY-108662
<b>CAS No.:</b>	56583-49-4
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>16</sub> N <sub>2</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	396.42
<b>Target:</b>	P2Y Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 83.33 mg/mL (210.21 mM); ultrasonic and warming and heat to 70°C																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.5226 mL</td> <td>12.6129 mL</td> <td>25.2258 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5045 mL</td> <td>2.5226 mL</td> <td>5.0452 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2523 mL</td> <td>1.2613 mL</td> <td>2.5226 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.5226 mL	12.6129 mL	25.2258 mL	5 mM	0.5045 mL	2.5226 mL	5.0452 mL	10 mM	0.2523 mL	1.2613 mL	2.5226 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.5226 mL	12.6129 mL	25.2258 mL																		
	5 mM	0.5045 mL	2.5226 mL	5.0452 mL																		
	10 mM	0.2523 mL	1.2613 mL	2.5226 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.25 mM); Clear solution																					

## BIOLOGICAL ACTIVITY

<b>Description</b>	PIT (2,2'-Pyridylisatogen tosylate) is a selective and non-competitive antagonist of P2Y1 receptor with an IC <sub>50</sub> value of 0.14 μM for human P2Y1 receptor. PIT antagonizes P2Y1 receptor signaling without affecting nucleotide binding. PIT is an irreversible antagonist of responses to ATP at metabotropic purinoceptors (of the P2Y family) in some smooth muscles. PIT can be used for the research of chronic bronchitis and asthma <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	P2Y1 Receptor 0.14 μM μM (IC <sub>50</sub> )
<b>In Vitro</b>	PIT (0.1-10 μM) non-competitively and dose-dependently diminishes human P2Y1 receptor signaling with an IC <sub>50</sub> value of 0.14 μM <sup>[1]</sup> . PIT (0.1-10 μM) completely blocks the agonist activity of 2-MeSADP <sup>[1]</sup> . PIT (1 nM-10 μM) dose-dependently inhibits the accumulation of inositol phosphates induced by the agonist 2-MeSADP <sup>[1]</sup> . PIT (1 nM-10 μM) dose-dependently blocks the P2Y1 receptor signaling induced by the endogenous agonist ADP <sup>[1]</sup> . PIT (0.1-3 μM) increases ATP-responses 2-5 fold, while higher concentrations (3-100 μM) inhibits ATP-mediated inward

---

	<p>current with an IC<sub>50</sub> value of 13.2 μM<sup>[2]</sup>.</p> <p>PIT shows a low affinity for a range of membrane receptors, including: α<sub>1</sub>, α<sub>2</sub>-adrenoceptors, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, D<sub>1</sub>, D<sub>2</sub>, muscarinic, central benzodiazepine, H<sub>1</sub>, μ-opioid, dihydropyridine and batrachotoxin receptors with pK<sub>i</sub> values of &lt;5<sup>[2]</sup>.</p> <p>PIT shows affinity to an adenosine (A<sub>1</sub>) receptor with a pK<sub>i</sub> value of 5.3<sup>[2]</sup>.</p> <p>PIT (12.5-50 μM) irreversibly antagonizes relaxations of ATP in guinea-pig isolated taenia caeca<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>PIT (10 mg/kg; i.p.; for 5 days) significantly protects both the white matter and the cortical plate lesions against the insult in mice with S-bromo-willardiine injection induced tonic and tonicoclonic seizures<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## REFERENCES

- [1]. Gao ZG, et al. 2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. *Biochem Pharmacol.* 2004 Jul 15;68(2):231-7.
- [2]. King BF, et al. Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. *Br J Pharmacol.* 1996 Mar;117(6):1111-8.
- [3]. Menton K, et al. Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2'-pyridylisatogen tosylate and related compounds. *Eur J Pharmacol.* 2002 May 24;444(1-2):53-60.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA